The Transforming Acidic Coiled-Coil 1 (TACC1) protein belongs to the TACC family, which includes TACC1. TACC2. and TACC3. These proteins share a conserved C-terminal coiled-coil domain and are implicated in regulating cell cycle progression, mitotic spindle assembly, and genomic stability. TACC1 is ubiquitously expressed, with prominent roles in embryonic development and tissue homeostasis. It localizes to the nucleus and interacts with chromatin-modifying complexes, transcription factors, and cytoskeletal components, suggesting dual functions in transcriptional regulation and mitotic organization. Dysregulation of TACC1 has been linked to cancers, including breast cancer and glioblastoma, where it may promote tumorigenesis by enhancing cell proliferation, survival, or metastasis. However, its precise mechanisms remain debated, with context-dependent oncogenic or tumor-suppressive roles reported.
TACC1 antibodies are essential tools for studying its expression patterns, subcellular localization, and interactions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess TACC1 levels in normal vs. diseased tissues. Commercial antibodies often target specific epitopes within its N-terminal or coiled-coil domains. Validation remains critical, as TACC1 shares homology with TACC2/3. raising potential cross-reactivity concerns. Research using these antibodies has advanced understanding of TACC1's involvement in chromatin remodeling, DNA damage response, and its crosstalk with signaling pathways (e.g., EGFR, RAS/MAPK). Ongoing studies aim to clarify its therapeutic potential as a biomarker or target in cancer and developmental disorders.